Clinical Trials - Patient

Clinical Trials - Patient

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer(S1802) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a Fusion of FGFR1, FGFR2, or FGFR3 (FUZE) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A BioMarker Driven Protocol for Previously Treated ALK-Positive NonSquamous NonSmall Cell Lung Cancer (LU003)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Blood Collection Study to Establish the Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early NonResponse to Therapy in Metastatic Cancer (CADEX-001)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Dose Escalation and Expanded Cohort Study of PF06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer, Castration-Resistant Prostate Cancer, and Follicular Lymphoma (C2321001 I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Dose Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors (XL184-021) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (SKI-G-801) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Double Blind Study of Pembrolizumab+Docetaxel+Prednisone vs Placebo+Docetaxel+Prednisone in Patients with Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer who have Progressed on Next Generation Hormonal Agent (MK3475-921) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Double Blind Trial of Pembrolizumab Plus Enzalutamide vs Placebo Plus Enzalutamide In Patients with Metastatic Castration-Resistant Prostate Cancer (MK3475-641) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated NonSmall Cell Lung Cancer (LUNGMAP)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Ibrutinib in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma(PERSPECTIVE) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Open-label Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338- 063) (16238) III
Mary Beth WIlwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody as Monotherapy or in Combination in Patients with Advanced Solid Tumors (CDX1140-01) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) (18164)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (LYNK-002) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Prospective Multicenter Non-interventional Study of Patients Receiving Palbociclib in Advanced Breast Cancer (Polaris) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Double Blind Study of Adjuvant Immunotherapy with Nivolumab vs Placebo After Complete Resection of Stage IIb/C Melanoma (CA209-76K) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Double Blind Study of Cabozantinib in Combinaiton with Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced or Metastatic Renal Cell Cancer of Intermediate or Poor Risk (XL184-313) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients wtih Metastatic Castration-Resistant Prostate Cancer (13Y-MC-JPCM) (18128) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (S1500) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Phase II/III Study of Conventional Chemotherapy Plus or Minus Uproleselan in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (A041701)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Placebo-Controlled, Double-Blinded, Multicenter, International Study of Durvalumab Following Stereotactic Body Radiation Therapy for the Treatment of Patients with Unresected Stage I/II Lymph Node Negative NonSmall Cell Lung Cancer (Pacific4) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Post Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple Negative Breast Cancer following Neo-Adjuvant Chemotherapy (EA1131) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study Comparing Two Intermittent Dosing Schedules of Duvelisib In Subjects with Indolent NonHodgkins Lymphoma (VS-0145-229) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study Evaluating the Efficacy and Safety of Canakinumab vs Placebo as Adjuvant Therapy in Subjects with Stages II-IIIA and IIIB Completely Resected NonSmall Cell Lung Cancer (17167) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members